Printer Friendly

SYVA INTRODUCES NEW AUTOMATED IMMUNODIAGNOSTIC SYSTEM

 SYVA INTRODUCES NEW AUTOMATED IMMUNODIAGNOSTIC SYSTEM
 SAN JOSE, Calif., Oct. 8 /PRNewswire/ -- Syva Company, the


diagnostics business of Syntex Corp. (NYSE: SYN), today introduced the Vista(R) Immunoassay System for marketing in the United States and Europe. This is Syva's latest entry into the medical diagnostics field, a fast-growing segment of the health care market. The total world-wide market for immunoassay testing is estimated to be $1.5 billion and growing at the rate of 10 percent per year.
 Tests for human disorders, including thyroid dysfunction, anemia, infertility, hepatitis, AIDS and cancer, have been developed by Syva for use on the system. The Vista system will launch with tests for thyroid function. In the near future, Syva will introduce tests for anemia, fertility and cancer, followed by hepatitis and AIDS. More than 35 tests are scheduled for the Vista system over the next few years. These tests are now in development and will be available after clearance by the U.S. Food and Drug Administration.
 Marketed exclusively by Syva, the Vista system includes an analyzer manufactured by Hitachi Ltd., of Japan, and biochemical assays developed by Syva. Vista is a highly automated system that will enhance both the efficiency and cost-effectiveness of diagnostic testing in hospital and commercial laboratories which run large numbers of tests on patients' blood plasma and serum samples.
 Syva's Vista system will be able to run up to 15 different tests on a single blood sample, allowing the laboratory to perform a wide variety of tests and provide results the same day. In one eight-hour work shift, the Vista system is capable of running more than 200 tests.
 These tests use a heterogeneous fluorescent enzyme immunoassay system with patented magnetic chromium dioxide particles. The advantages of magnetic chromium dioxide particles include high surface area, easy dispersion, rapid analyte capture, and low non-specific binding. This technology enables the clinician to measure a wide variety of special chemistry analytes with very accurate results.
 Vista complements Syva's Emit(R) and MicroTrak(R) immunoassay product lines and expands Syva's presence in the automated immunoassay marketplace. According to Richard Bastiani, Ph.D., president of Syva, Vista is an "exciting new development in an important field and a major milestone in Syva's efforts to improve diagnostic tests for human diseases and increase the cost-effective delivery of health care."
 Syva, a Syntex company, is a developer, manufacturer, and marketer of medical diagnostic tests and instruments. Syntex Corporation is an international health care company engaged in the research, development, manufacturing, and marketing of human and animal pharmaceuticals and medical diagnostics.
 -0- 10/9/92 R
 /CONTACT: Suzanne Ward-Seidel of Syva Company, 408-239-2585/
 (SYN) CO: Syva Company; Syntex Corp. ST: California IN: MTC SU: PDT


TB -- SJ004 -- 8193 10/09/92 08:00 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 9, 1992
Words:459
Previous Article:GEORGIA-PACIFIC ENTERS AGREEMENT IN PRINCIPLE TO SELL BELLINGHAM LIGNOSULFONATE AND ALCOHOL PLANTS
Next Article:COLUMBIA BANKING SYSTEM TO ACQUIRE FIRST AMERICAN STATE BANK
Topics:


Related Articles
SYVA INTRODUCES NEW AUTOMATED IMMUNODIAGNOSTIC SYSTEM
SYVA INTRODUCES MICROTRAK XL
OLYMPUS AMERICA, BEHRING DIAGNOSTICS TO CO-MARKET GENERAL CHEM ANALYZER AND EMIT(R) ASSAYS TO HOSPITAL LABS
BIOCIRCUITS APPOINTS WILLIAM M. WRIGHT AS VICE PRESIDENT OF OPERATIONS
American Bio Medica A FULLY REPORTING COMPANY
Biocircuits Corporation Receives $5.8 Million in Completion Of Private Placement
Ortho-Clinical Diagnostics, a Johnson & Johnson Company: Ten New Assays Propel VITROS(R) Systems to Forefront of Laboratory Instrumentation.
Dade Behring Launches New Drugs-of-Abuse Testing Capabilities.
Ortho-Clinical Diagnostics receives FDA approval for new HIV test.
Immunoassay Automation: an Updated Guide to Systems.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters